Ocrelizumab and Rituximab for the Treatment of Multiple Sclerosis Patients: A Real-World Clinical Experience
Comparing Ocrelizumab and Rituximab in MS Treatment
DOI:
https://doi.org/10.22317/jcms.v11i4.1916Keywords:
Expanded disability status scale (EDSS); multiple sclerosis; ocrelizumab; rituximab treatment naïve.Abstract
Objective: The aim was to describe real clinical experience in using ocrelizumab (OCR) or rituximab (RTX) treatment for naive and previously treated multiple sclerosis (MS) patients. Looking for change in disability and clinical safety. Comparing the present EDSS status with other large studies world-wide was well thought-out.
Methods: This work included 75 MS patients. Their characteristics including age, disease duration, age at onset, gender and type of MS were recorded as well as previous medications received before introducing OCR/RTX and any side effects. The EDSS was assessed.
Results: The mean age of patients was 34.1±9.6 years, disease duration 6.2±5.1 years and age at onset 28±8.5 years. F:M was 1.3:1. 88% were relapsing-remitting (RRMS) and 12% secondary-progressive (SPMS). 37 received OCR and 38 RTX for treatment-naive (49.3%) or previously treated MS patiens (50.7%) cases for a duration of 3.18±1.38 years. The baseline EDSS (2.43±1.32) significantly decreased after treatment (1.69±2.03,p=0.014) especially in those receiving OCR (p=0.021). Relapse was present in 5.3%, side effects occurred in 8% of cases and only one deceased following RTX. Late-onset (LOMS)(n=2) had higher EDSS scores. SPMS patients had significantly higher EDSS before (p=0.003) and after (p<0.0001) receiving OCR/RTX compared to RRMS. EDSS significantly correlated with age (r=0.28,p=0.018) and could significantly discriminate both types (p<0.0001).
Conclusion: Both ocrelizumab and rituximab were effective in halting the disability in MS cases with acceptable safety. The EDSS was remarkably related to the age being higher in those with LOMS.
References
Holm RP, Wandall-Holm MF, Sellebjerg F, Magyari M. Comorbidity in the aging population with multiple sclerosis: a Danish nationwide study. Front Neurol. 2023;14:1297709.
Leal Rato M, Santos M, de Sá J, Ferreira J. Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study. J Neuroimmunol. 2023;385:578226.
Machado A, Azad A, Pettersson E, Hillert J, Alexanderson K, Friberg E. Gender differences in earnings among people with multiple sclerosis and associations with type of occupation and family composition: A population-based study with matched references. PLoS One. 2023;18(8):e0288998
Alswat AM, Altirkistani BA, Alserihi AR, Baeshen OK, Alrushid ES, Alkhudair J, et al. The prevalence of major depression and generalized anxiety disorder in patients with multiple sclerosis in Saudi Arabia: a cross-sectional multicentered study. Front Psychiatry. 2023;14:1195101
Efendi H. Clinically Isolated Syndromes: Clinical characteristics, differential diagnosis, and management. Noro Psikiyatr Ars. 2015;52(Suppl 1):S1-S11
AlJumah M, Bunyan R, Al Otaibi, H. Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. BMC Neurol. 2020;20:49.
Ma X, Ma R, Zhang M, Qian B, Wang B, Yang W. Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets. Pharmaceutics. 2023;15(3):728.
Füvesi J. The expanded disability status scale scoring in patients with multiple sclerosis. Ideggyogy Sz. 2019;72(9-10):317-23.
Muros-Le Rouzic E, Ghiani M, Zhuleku E, Dillenseger A, Maywald U, Wilke T, et al. Claims-based algorithm to estimate the expanded disability status scale for multiple sclerosis in a German health insurance fund: a validation study using patient medical records. Front Neurol. 2023;14:1253557.
Romeo AR, Rowles WM, Schleimer ES, Barba P, Hsu WY, Gomez R, et al. An electronic, unsupervised patient-reported expanded disability status scale for multiple sclerosis. Mult Scler. 2021;27(9):1432-41.
Alves P, Green E, Leavy M, Friedler H, Curhan G, Marci C, et al. Validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis. Mult Scler J Exp Transl Clin. 2022;8(2):20552173221108635.
Lynch S, Baker S, Nashatizadeh M, Thuringer A, Thelen J, Bruce J. Disability measurement in Multiple Sclerosis patients 55 years and older: What is the expanded disability status scale really telling clinicians? Mult Scler Relat Disord. 2021;49:102724
Bovis F, Signori A, Carmisciano L, Maietta I, Steinerman JR, Li T, et al. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. Ann Neurol. 2018;84(4):621-5.
Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, et al. Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler.2011;17(8):970-9
Thompson A, Baranzini S, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. The Lancet. 2018;391(10130):1622–36.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52
Mazdeh M, Kargar Monhaser S, Taheri M, Ghafouri-Fard S. A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients. Clin Transl Med. 2019;8(1):11.
Langer-Gould A, Sotirchos ES, Bourdette D. Rituximab for multiple sclerosis. Neurology. 2024;102(2):e208063.
Alping P. Disease-modifying therapies in multiple sclerosis: A focused review of rituximab. Basic Clin Pharmacol Toxicol. 2023;133(5):550-64.
Çinar BP, Yorgun YG. What we learned from the history of multiple sclerosis measurement: Expanded disability status scale. Noro Psikiyatr Ars. 2018;55(Suppl 1):S69-S75.
Prajjwal P, MDM M, Natarajan B, Inban P, Gadam S, Sowndarya D, et al. Juvenile multiple sclerosis: addressing epidemiology, diagnosis, therapeutic, and prognostic updates along with cognitive dysfunction and quality of life. Ann Med Surg (Lond). 2023;85(9):4433-41.
Moura J, Duarte S, Oliveira V, Pereira D, Costa D, Samões R, et al. Characterization of a late-onset multiple sclerosis Portuguese cohort. Mult Scler Relat Disord. 2023;70:104506.
Jerković A, Pavelin S, Šoda J, Vujović I, Rogić Vidaković M. Symptom-level disability status assessed with an electronic unsupervised patient-reported expanded disability status scale (ePR-EDSS) in multiple sclerosis patients-The example of Croatia. J Clin Med. 2022;11(14):4081.
Li J, Huang Y, Hutton GJ, Aparasu RR. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. Explor Res Clin Soc Pharm. 2023;11:100307
Al-Keilani MS, Almomani BA. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study. Int J Pharm Pract. 2023;31(2):198-205
Mazdeh M, Khamseh M, Taheri M, Ghafouri-Fard S. Effect of rituximab on expanded disability status scale and relapse rate in multiple sclerosis patients. J Mol Neurosci. 2020;70(8):1165-8
Al-Roughani R, Zakaria M, Cupler EJ, Taha K. Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study. Front Neurol. 2023;14:1257455
Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P et al. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving expanded disability status scale reference analysis from the Italian multiple sclerosis register. Eur J Neurol. 2021;28(2):567-78.
Sabanagic-Hajric S, Memic-Serdarevic A, Sulejmanpasic G, Salihovic-Besirovic D, Kurtovic A, Bajramagic N, et al. Cognitive imapirment in multiple sclerosis: Relation to dysability, duration and type of disease. Mater Sociomed. 2023;35(1):23-7
Skalli A, Ait Ben Haddou EH, El Jaoudi R, Razine R, Mpandzou GA, Tibar H, El Fahime E, Bouslam N, Alami A, Benomar A, Hajjout K, Yahyaoui M, Bouhouche A. Association of vitamin D status with multiple sclerosis in a case-control study from Morocco. Rev Neurol (Paris). 2018;174(3):150-6
Hosny HS, Shehata HS, Ahmed S, Ramadan I, Abdo SS, Fouad AM. Predictors of severity and outcome of multiple sclerosis relapses. BMC Neurol. 2023;23(1):67.
Evdoshenko E, Stepanova A, Shumilina M, Davydovskaya M, Khachanova N, Neofidov N, et al. Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia. PLoS One. 2019;14(5):e0217303
Omrani MA, Bayati A, Sahraian MA, Eskandarieh S. Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran. Curr J Neurol. 2023;22(2):103-9
Türk Börü Ü, Duman A, Kulualp AŞ, Güler N, Taşdemir M, Yılmaz Ü, et al. Multiple sclerosis prevalence study: The comparison of 3 coastal cities, located in the black sea and mediterranean regions of Turkey. Medicine (Baltimore). 2018;97(42):e12856.
Bu B, Quan C, Li W, Zeng Q, Shi Z, Chen B, et al. The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis. Ther Adv Neurol Disord. 2023;16:17562864231181170.
Barreiro-González A, Sanz MT, Carratalà-Boscà S, Pérez-Miralles F, Alcalá C, Carreres-Polo J, et al. Design and validation of an expanded disability status scale model in multiple sclerosis. Eur Neurol. 2022;85(2):112-21.
Cadavid D, Tang Y, O'Neill G. Responsiveness of the expanded disability status scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol. 2010;51(6):321-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
